The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was first identified in the state of Maharashtra in late 2020 and spread throughout India, …

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) virus, leads to respiratory symptoms that can be fatal. However, …

Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infects cells by binding to
the host cell receptor ACE2 and undergoing virus-host membrane fusion. Fusion is …

Here, we identify (−)‐epigallocatechin‐3‐gallate (EGCG) as a new inhibitor of hepatitis C
virus (HCV) entry. EGCG is a flavonoid present in green tea extract belonging to the subclass …

Hepatitis C virus (HCV) particles are known to be in complex with lipoproteins. As a result of
this interaction, the low‐density lipoprotein (LDL) receptor (LDLR) has been proposed as a …

Hepatitis C virus (HCV)-infected patients undergoing liver transplantation universally experience
rapid reinfection of their new liver graft. Current treatment protocols do not prevent graft …

The SARS-CoV-2 B. 1.617. 2 (Delta) variant was first identified in the state of Maharashtra in
late 2020 and spread throughout India, outcompeting pre-existing lineages including B. …

Herpes simplex virus type-1 (HSV-1) is one of the most widespread pathogens among
humans. Although the structure of HSV-1 has been extensively investigated, the precise …

COVID-19 has stimulated the rapid development of new antibody and small molecule
therapeutics to inhibit SARS-CoV-2 infection. Here we describe a third antiviral modality that …

HIV-1 Gag metamorphoses inside each virion, from an immature lattice that forms during viral
production to a mature capsid that drives infection. Here we show that the immature lattice …